Recombinant Human TAFA4/FAM19A4 Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human TAFA4/FAM19A4 Protein, CF Summary

• Details of Functionality: Measured by its ability to enhance neurite outgrowth of E16-E18 rat embryonic cortical neurons. rhTAFA4, immobilized at 6-24 μg/mL on a 96-well plate, is able to significantly enhance neurite outgrowth.
• Source: E. coli-derived human TAFA4/FAM19A4 protein
  Ser35-Arg140
• Accession #: NP_001005527
• N-terminal Sequence: Ser35
• Protein/Peptide Type: Recombinant Proteins
• Gene: FAM19A4
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Endotoxin Note: <0.01 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 11.7 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 11 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Reconstitution Instructions: Reconstitute at 200 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human TAFA4/FAM19A4 Protein, CF

• Chemokine-like protein TAFA-4
• FAM19A4
• family with sequence similarity 19 (chemokine (C-C motif)-like), member A4
• FLJ25161
• TAFA4
• TAFA-4

Background

TAFA4 (also FAM19A4) is a secreted, 12 kDa member of the FAM19/TAFA family of chemokine-like proteins (1). It is synthesized as a 140 amino acid (aa) precursor that contains a 35 aa signal sequence and a 105 aa mature chain (SwissProt #: Q96LR4). Like other members of the FAM19/TAFA family, with the exception of TAFA5, mature TAFA4 contains 10 regularly spaced cysteine residues that follow the pattern CX₇CCX₁₃CXCX₁₄CX₁₁CX₄CX₅CX₁₀C, where C represents a conserved cysteine residue and X represents any noncysteine amino acid (1). Human TAFA4 is 90% aa identical to mouse TAFA4 (1). Real-time PCR analysis indicates that TAFA4 mRNA expression is restricted to the central nervous system (CNS), with the highest level in the thalamus (1). The biological functions of TAFA family members remain to be determined, but there are a few tentative hypotheses. First, TAFAs may modulate immune responses in the CNS by functioning as brain specific chemokines, and may act with other chemokines to optimize the recruitment and activity of immune cells in the CNS (1). Second, TAFAs may represent a novel class of neurokines that act as regulators of immune nervous cells (1 - 2). And third, TAFAs may control axonal sprouting following brain injury (1).

1. Tang, Y.T. et al. (2004) Genomics 83:727.
2. Benveniste, E. (1998) Cytokine Growth Factor Rev. 9:259.

Publications for TAFA4/FAM19A4 (5099-TA)(1)

Publication using 5099-TA

• Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature, 2012-07-26;487(7408):505-9. 2012-07-26 [PMID: 22763448] (Bioassay, Human)

Bioinformatics

• Gene Symbol: FAM19A4
• Uniprot:
  • NP_001005527()